Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose dalbavancin vs standard therapy for Staphylococcus aureus catheter-related bloodstream infection
2021-004038-12Phase 3Active
- Sponsor
- Centre Hospitalier Annecy Genevois
- Start
- Oct 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dalbavancin in Staphylococcus aureus catheter-related bloodstream infection (2 arms), sponsored by Centre Hospitalier Annecy Genevois. Started Oct 2021; status: active.
02
Drugs
dalbavancin
03
Conditions
Staphylococcus aureus catheter-related bloodstream infection
Beyond the preview
Go deeper on 2021-004038-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004038-12.